{"filing":{"accession_number":"0001640334-26-001384","cik":"0001348362","ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"lxrp_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001384/lxrp_8k.htm"},"events":[{"id":28200,"run_id":25782,"accession_number":"0001640334-26-001384","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The filing discloses that Lexaria has cured a Nasdaq bid price deficiency and regained compliance with Listing Rule 5550(a)(2), resulting in cancellation of a previously requested delisting hearing. While the news is positive (cure achieved), the disclosure itself centers on a delisting risk event—the company was previously non-compliant with continued listing standards and faced potential delisting. This is material to investors as it directly affects the registrant's exchange listing status.","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30060,"accession_number":"0001640334-26-001384","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses that Lexaria has cured a Nasdaq bid price deficiency and regained compliance with Listing Rule 5550(a)(2), resulting in cancellation of a previously requested delisting hearing. While the news is positive (cure achieved), the disclosure itself centers on a delisting risk event—the company was previously non-compliant with continued listing standards and faced potential delisting. This is material to investors as it directly affects the registrant's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T16:38:52.636031+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30060,"accession_number":"0001640334-26-001384","item_number":"8.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses that Lexaria has cured a Nasdaq bid price deficiency and regained compliance with Listing Rule 5550(a)(2), resulting in cancellation of a previously requested delisting hearing. While the news is positive (cure achieved), the disclosure itself centers on a delisting risk event—the company was previously non-compliant with continued listing standards and faced potential delisting. This is material to investors as it directly affects the registrant's exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T16:38:52.636031+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-08-17"}]}